CN102018721A - Chewable tablet of calcium carbonate dimeticone and preparation process - Google Patents
Chewable tablet of calcium carbonate dimeticone and preparation process Download PDFInfo
- Publication number
- CN102018721A CN102018721A CN2009102721884A CN200910272188A CN102018721A CN 102018721 A CN102018721 A CN 102018721A CN 2009102721884 A CN2009102721884 A CN 2009102721884A CN 200910272188 A CN200910272188 A CN 200910272188A CN 102018721 A CN102018721 A CN 102018721A
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- dimeticone
- chewable tablet
- cross
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 33
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 title claims abstract description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 8
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 8
- 229960001275 dimeticone Drugs 0.000 title claims abstract description 6
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 title claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 4
- 108010011485 Aspartame Proteins 0.000 claims abstract description 3
- 229920002261 Corn starch Polymers 0.000 claims abstract description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 3
- 239000000605 aspartame Substances 0.000 claims abstract description 3
- 235000010357 aspartame Nutrition 0.000 claims abstract description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 3
- 229960003438 aspartame Drugs 0.000 claims abstract description 3
- 239000008120 corn starch Substances 0.000 claims abstract description 3
- 235000010355 mannitol Nutrition 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- -1 siliciidoxydum Chemical compound 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940008099 dimethicone Drugs 0.000 claims description 10
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 10
- 229940069428 antacid Drugs 0.000 claims description 7
- 239000003159 antacid agent Substances 0.000 claims description 7
- 230000001458 anti-acid effect Effects 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 4
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract description 3
- 239000006260 foam Substances 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 229940083037 simethicone Drugs 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract 1
- 206010051986 Pneumatosis Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 238000012216 screening Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013530 defoamer Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940032120 simethicone 21 mg Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940085871 calcium carbonate 420 mg Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940035288 titralac Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a chewable tablet of calcium carbonate dimeticone and a preparation process, belonging to four new national chemical medicines. The preparation of the invention is prepared from the following main components: calcium carbonate, simethicone, siliciidoxydum, aspartame, essence powder, mannite, corn starch, low-substituted hydroxypropyl cellulose and magnesium stearate, wherein the calcium carbonate as the main content has stronger acid-resisting action and rapid and lasting effects, and the simethicone is a foam suppressor for eliminating gastrointestinal tract pneumatosis. The preparation is used for treating peptic ulcers including stomach and duodenal ulcer and easing various uncomfortable symptoms caused by hyperacidity.
Description
Technical field
The invention belongs to traditional Chinese medicines chemical drugs four kind new medicines.
Background technology
Peptic ulcer bag gastric duodenal ulcer is a kind of time-honored commonly encountered diseases, the sickness rate average out to 8-10% in the crowd.The reasonability of antacid and medication inexpensive because of it, and meet current national Health care system, be a kind of main medicine of treatment peptic ulcer.Antacid is generally alkaline compound, thus in vivo can in and gastric acid remove its stimulation and damage to the gastric duodenal ulcer face, can relief of symptoms, help the reparation of ulcer.Clinically compound recipes that adopt antacid and other drug to form, defoamer is for wherein a kind of more.Defoamer can be eliminated the foam in the gastrointestinal tract because surface tension is little, and the gas of being stored by foam is released, and alleviates flatulence, and the gastrointestinal tract flatulence that a variety of causes is caused has positive effect.This product is the compound preparation of antacid calcium carbonate and defoamer dimethicone.
Summary of the invention
The present invention has mainly provided a kind of new antacid class and has treated the prescription and the preparation technology of the chemical drugs of gastric duodenal ulcer, and said preparation prescription and preparation technology are domestic to be used as yet.
Prescription of the present invention is: calcium carbonate, 420.0g; Dimethicone, 20.0g; Micropowder silica gel, 1.0g; Aspartame, 3.0g; Powdered flavor, 3.0g; Mannitol, 200.0g; Corn starch, 13.5g; Low-substituted hydroxypropyl cellulose, 15.0g; Magnesium stearate, 4.0g.
Preparation technology of the present invention is: (1) presses recipe quantity with dimethicone, micropowder silica gel mix homogeneously, adds the calcium carbonate of crossing 120 mesh sieves again and fully mixes, and it is standby to cross 40 mesh sieves.(2) other adjuvants of having crossed mesh sieve except that magnesium stearate are added in (1), cross 80 mesh sieve mix homogeneously.(3) add 5% and decide the powder slurry and make soft material, cross the granulation of 16 orders.(4) put in 50 ℃ of baking ovens and dry.Press recipe quantity in the granule and add magnesium stearate, cross 20 order granulate.Survey in the granule behind the drug content tabletting.
The specific embodiment
With reference to the Titralac of Minnesota Mining and Manufacturing Company
TMThe dose prescription of plus Antacid chewable tablet is formed: every contains calcium carbonate 420mg, Simethicone 21mg, the wherein mixture of Simethicone dimethicone and silicon dioxide.Dimethicone is an active substance; The micropowder silica gel main component is a silicon dioxide, and to increase the distribution area of dimethicone, content is 4～7% as dispersant.
(3)Adopt external report method with 20mg dimethicone and 1mg micropowder silica gel mix homogeneously in this research, its semi-solid material is equivalent to Simethicone 21mg.
In the prescription screening process, because 3M company's T itralac
TMPlus Antacid chewable tablet both can be chewed, and can swallow again, so be index with mouthfeel, outward appearance and the disintegrate etc. of tablet mainly, investigated disintegrate emphatically, by selecting different adjuvants and consumption for use, determined more reasonably prescription.
Concrete screening process sees the following form.
Table 1: prescription screening
Annotate: L-HPC for low-substituted hydroxypropyl cellulose CMS-Na for completing methyl starch sodium
Through prescription screening, the 4 gained tablet mouthfeels of writing out a prescription.Outward appearance and disintegrate are all better.So select for use this prescription as final prescription.
Claims (3)
1. calcium carbonate dimeticone chewable tablet active ingredient is: antacid calcium carbonate, froth breaking medicine dimethicone.
2. calcium carbonate dimeticone chewable tablet prescription is: calcium carbonate, 420.0g; Dimethicone, 20.0; Micropowder silica gel, 1.0g; Aspartame, 3.0g; Powdered flavor, 3.0g; Mannitol, 200.0g; Corn starch, 13.5g; Low-substituted hydroxypropyl cellulose, 15.0g; Magnesium stearate, 4.0g.
3. the preparation technology of calcium carbonate dimeticone chewable tablet: (1) presses recipe quantity with dimethicone, micropowder silica gel mix homogeneously, adds the calcium carbonate of crossing 120 mesh sieves again and fully mixes, and it is standby to cross 40 mesh sieves.(2) other adjuvants of having crossed mesh sieve except that magnesium stearate are added in (1), cross 80 mesh sieve mix homogeneously.(3) add 5% and decide the powder slurry and make soft material, cross the granulation of 16 orders.(4) put in 50 ℃ of baking ovens and dry.Press recipe quantity in the granule and add magnesium stearate, cross 20 order granulate.Survey in the granule behind the drug content tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018721A true CN102018721A (en) | 2011-04-20 |
| CN102018721B CN102018721B (en) | 2012-08-22 |
Family
ID=43860771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102721884A Expired - Fee Related CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018721B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523717A (en) * | 2015-01-06 | 2015-04-22 | 西南大学 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
| CN106860475A (en) * | 2017-02-17 | 2017-06-20 | 北京沃邦医药科技有限公司 | A kind of preparation method of calcium carbonate D3 tablets |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637313A (en) * | 1994-12-16 | 1997-06-10 | Watson Laboratories, Inc. | Chewable dosage forms |
-
2009
- 2009-09-23 CN CN2009102721884A patent/CN102018721B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523717A (en) * | 2015-01-06 | 2015-04-22 | 西南大学 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
| CN106860475A (en) * | 2017-02-17 | 2017-06-20 | 北京沃邦医药科技有限公司 | A kind of preparation method of calcium carbonate D3 tablets |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018721B (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI257311B (en) | Rapidly disintegrable solid preparation | |
| RU2201216C2 (en) | Rapidly cleaving pharmaceutical medicinal form | |
| MXPA04000223A (en) | Novel substituted benzimidazole dosage forms and method of using same. | |
| JP6250100B2 (en) | Pharmaceutical composition for oral administration for treatment of irritable bowel syndrome comprising intestinal motility regulator, gas retention inhibitor and digestive enzyme, and preparation method thereof | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| JP4939680B2 (en) | Solid preparation | |
| CN102018721B (en) | Chewable tablet of calcium carbonate dimeticone and preparation process | |
| CN101564402A (en) | Rehabilitation new dispersing tablet and preparation method thereof | |
| CN102512402B (en) | Novel preparation of medicine for treating gastric and duodenal ulcers and preparation method thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101234094B (en) | Dipyridamole orally disintegrating tablet | |
| CN100471497C (en) | Naloxone Hydrochloride nose powder preparation | |
| CN101269055B (en) | Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same | |
| CN101099747A (en) | Compound alginic acid chewing tablet and preparation method thereof | |
| CN101574320A (en) | Intestinal protection medicament and preparation method thereof | |
| CN103877036A (en) | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof | |
| CN101152187A (en) | Eplerenone pharmaceutical composition | |
| CN103405471A (en) | Compound preparation containing ilaprazole sodium | |
| CN102370621A (en) | Solid preparation with cefotiam hexetil as active component | |
| CN102488708B (en) | Magaldrate chewable tablets and preparation method thereof | |
| CN102266284A (en) | Secnidazole pessary and preparation process thereof | |
| CN101926798B (en) | Dispersible tablet containing amlodipine and valsartan | |
| CN101862344B (en) | Mouthwash preparation containing nysfungin | |
| CN1689643A (en) | Lactoferrin chewing tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200810 Address after: 430000 Guannan science and Technology Industrial Park, Donghu Development Zone, Wuhan City, Hubei Province Patentee after: Hubei Huquan Pharmaceutical Co.,Ltd. Address before: 430073, No. 81 Nanhu Avenue, Guan Nan Industrial Park, East Lake New Technology Development Zone, Hubei, Wuhan Patentee before: HUANGSHI LISHIZHEN PHARMACEUTICAL GROUP WUHAN LISHIZHEN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 |